ライフサイエンスコーパス: flu-like symptom

1 stly of mild and transient injection site or flu-like symptoms.

2 of abdominal distention, fevers, chills, and flu-like symptoms.

3 effects were limited primarily to transient flu-like symptoms.

4 city was manageable, consisting primarily of flu-like symptoms.

5 to-transmitted alphavirus that causes severe flu-like symptoms.

6 mogeneous or central redness and nonspecific flu-like symptoms.

7 r function, and a single patient with severe flu-like symptoms.

8 on until at least 26 days after the onset of flu-like symptoms.

9 eaction was defined as a grade >=2 of any of flu-like symptoms.

10 scontinued due mostly to musculoskeletal and flu-like symptoms.

11 ing fever, respiratory distress, nausea, and flu-like symptoms.

12 e factors emerged from the EFA: (1) cold and flu-like symptoms, (2) change in smell and/or taste, (3)

13 r toxicities during the first cycle included flu-like symptoms (21% of patients), fatigue (6% of pati

14 (78% with mipomersen, 31% with placebo) and flu-like symptoms (34% with mipomersen, 21% with placebo

15 transient post-DC infusion chills (38%) and flu-like symptoms (84%), dermatitis (64%), hepatitis (13

16 .8%, n = 293), headache (11.6%, n = 215) and flu-like symptoms (9.3%, n = 172) were most common.

17 aise after the first infliximab infusion and flu-like symptoms after the second one.

18 ute illness in humans, producing nonspecific flu-like symptoms and a biphasic fever in approximately

19 who presented with a 3-wk history of fever, flu-like symptoms and abdominal pain.

20 a zoonotic disease that presents with acute flu-like symptoms and can result in chronic life-threate

21 Common on-treatment adverse events included flu-like symptoms and elevated transaminase levels.

22 ine encephalitis virus (VEEV), which elicits flu-like symptoms and encephalitis in humans, with an es

23 Human brucellosis patients develop flu-like symptoms and focal complications including arth

24 ssa hemorrhagic fever in humans, begins with flu-like symptoms and leads to death approximately 2 wee

25 ptive transfer to be associated with grade I flu-like symptoms and malaise.

26 Treatment was well tolerated with minimal flu-like symptoms and no significant hematologic changes

27 ults with HMPV patients presenting with more flu-like symptoms and viral pneumonia.

28 Fever, flu-like symptoms, and fatigue occurred significantly mo

29 mon nonhematologic toxicities were asthenia, flu-like symptoms, and fluid retention.

30 nts), hematologic toxicity (seven patients), flu-like symptoms, and infection (five patients each).

31 The clinical picture is variable but flu-like symptoms are common with bilateral interstitial

32 a serious medical condition that presents as flu like symptoms but then often leads to more serious o

33 r first patient is a 31-year-old man who had flu-like symptoms due to COVID-19 and later developed an

34 icities related to virus administration were flu-like symptoms, emesis, and abdominal pain.

35 Adverse events consisted of flu-like symptoms (fever/chills, nausea/vomiting, and my

36 grade 1 to 2 pain at the injection site and flu-like symptoms following IDI, some patients receiving

37 nt data show that SARS-CoV-2 results in mild flu-like symptoms in the majority of healthy and young p

38 th D+G consisted largely of mild to moderate flu-like symptoms, including headache and fever, and occ

39 uine encephalitis virus (VEEV), which causes flu-like symptoms leading to neurological symptoms in up

40 mplications of IFNalpha2b included transient flu-like symptoms (n = 3), corneal epithelial defect (n

41 Common toxicities included flu-like symptoms, nausea, and emesis.

42 included mild to moderate mucocutaneous and flu-like symptoms; occasional significant fatigue (grade

43 Hypertensive events accompanied with flu-like symptoms occurred in 11.2% of elderly participa

44 rhagic fever characterized by rapid onset of flu-like symptoms often followed by hemorrhagic manifest

45 LD] or symptomatic EBV infection, defined as flu-like symptoms or infectious mononucleosis).

46 The most common adverse events included flu-like symptoms, pruritus, and rash.

47 rofile was characterized by common transient flu-like symptoms such as fever and chills.

48 olled and were stratified by the presence of flu-like symptoms (such as fever, chills, headache, mala

49 The most common adverse events were flu-like symptoms that occurred principally after the fi

50 ponsible for Q fever, a febrile illness with flu-like symptoms that often goes undiagnosed.

51 Acute human Q fever is characterized by flu-like symptoms that, in some cases, can result in a p

52 al conditions in children, ranging from mild flu-like symptoms to coma and death.

53 variable across patients, ranging from mild flu-like symptoms to fulminant hyperinflammatory states

54 Finally, flu-like symptoms were lower in the intervention group.

55 Flu-like symptoms were reported in one patient but not c

56 2 infection typically develop mild-to-severe flu-like symptoms, whereas infection of a subset of indi

57 nfection manifests as a febrile illness with flu-like symptoms, which can progress to encephalitis an

58 s of cytomegalovirus (CMV) infection include flu-like symptoms with fever, diarrhea, leukopenia, and